array(40) {
  [0]=>
  string(4) "7888"
  ["article_id"]=>
  string(4) "7888"
  [1]=>
  string(54) "Japan’s Takeda buys PvP Biologics in $330m deal"
  ["article_title"]=>
  string(54) "Japan’s Takeda buys PvP Biologics in $330m deal"
  [2]=>
  string(150) "PvP Biologics has been acquired following the conclusion of Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062), which is b"
  ["short_description"]=>
  string(150) "PvP Biologics has been acquired following the conclusion of Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062), which is b"
  [3]=>
  string(554) "
PvP Biologics has been acquired following the conclusion of Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062), which is being developed to treat uncontrolled celiac disease. The 
&#nl
The post Japan’s Takeda buys PvP Biologics in $330m deal appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(554) "
PvP Biologics has been acquired following the conclusion of Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062), which is being developed to treat uncontrolled celiac disease. The 
&#nl
The post Japan’s Takeda buys PvP Biologics in $330m deal appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(74) "https://www.pharmaceutical-business-review.com/news/jtakeda-pvp-biologics/"
  ["blog_url"]=>
  string(74) "https://www.pharmaceutical-business-review.com/news/jtakeda-pvp-biologics/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:57"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7889"
  ["article_id"]=>
  string(4) "7889"
  [1]=>
  string(67) "Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis"
  ["article_title"]=>
  string(67) "Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis"
  [2]=>
  string(150) "LXE408 was discovered at Novartis with the financial backing of the Wellcome Trust. According to Novartis, more than a billion people across the world"
  ["short_description"]=>
  string(150) "LXE408 was discovered at Novartis with the financial backing of the Wellcome Trust. According to Novartis, more than a billion people across the world"
  [3]=>
  string(548) "
LXE408 was discovered at Novartis with the financial backing of the Wellcome Trust. According to Novartis, more than a billion people across the world are at risk of 
&#nl
The post Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(548) "
LXE408 was discovered at Novartis with the financial backing of the Wellcome Trust. According to Novartis, more than a billion people across the world are at risk of 
&#nl
The post Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(96) "https://www.pharmaceutical-business-review.com/news/novartis-dndi-lxe408-visceral-leishmaniasis/"
  ["blog_url"]=>
  string(96) "https://www.pharmaceutical-business-review.com/news/novartis-dndi-lxe408-visceral-leishmaniasis/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:57"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7890"
  ["article_id"]=>
  string(4) "7890"
  [1]=>
  string(45) "AstraZeneca divests global rights to Movantik"
  ["article_title"]=>
  string(45) "AstraZeneca divests global rights to Movantik"
  [2]=>
  string(150) "Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). Ruud Dobber"
  ["short_description"]=>
  string(150) "Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). Ruud Dobber"
  [3]=>
  string(609) "
Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “This divestment 
&#nl
The post AstraZeneca divests global rights to Movantik appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(609) "
Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “This divestment 
&#nl
The post AstraZeneca divests global rights to Movantik appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(104) "https://www.pharmaceutical-business-review.com/news/deals/astrazeneca-divests-global-rights-to-movantik/"
  ["blog_url"]=>
  string(104) "https://www.pharmaceutical-business-review.com/news/deals/astrazeneca-divests-global-rights-to-movantik/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:57"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7891"
  ["article_id"]=>
  string(4) "7891"
  [1]=>
  string(84) "Lysogene receives FDA fast track designation for LYS-SAF302 gene therapy in MPS IIIA"
  ["article_title"]=>
  string(84) "Lysogene receives FDA fast track designation for LYS-SAF302 gene therapy in MPS IIIA"
  [2]=>
  string(150) "LYS-SAF302, a second-generation gene therapy, is designed to deliver a functional copy of the SGSH (N-sulfoglucosamine sulfohydrolase) gene to the bra"
  ["short_description"]=>
  string(150) "LYS-SAF302, a second-generation gene therapy, is designed to deliver a functional copy of the SGSH (N-sulfoglucosamine sulfohydrolase) gene to the bra"
  [3]=>
  string(649) "
LYS-SAF302, a second-generation gene therapy, is designed to deliver a functional copy of the SGSH (N-sulfoglucosamine sulfohydrolase) gene to the brain through a one-time direct-to-CNS administration, and is 
&#nl
The post Lysogene receives FDA fast track designation for LYS-SAF302 gene therapy in MPS IIIA appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(649) "
LYS-SAF302, a second-generation gene therapy, is designed to deliver a functional copy of the SGSH (N-sulfoglucosamine sulfohydrolase) gene to the brain through a one-time direct-to-CNS administration, and is 
&#nl
The post Lysogene receives FDA fast track designation for LYS-SAF302 gene therapy in MPS IIIA appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(137) "https://www.pharmaceutical-business-review.com/news/lysogene-receives-fda-fast-track-designation-for-lys-saf302-gene-therapy-in-mps-iiia/"
  ["blog_url"]=>
  string(137) "https://www.pharmaceutical-business-review.com/news/lysogene-receives-fda-fast-track-designation-for-lys-saf302-gene-therapy-in-mps-iiia/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:57"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7892"
  ["article_id"]=>
  string(4) "7892"
  [1]=>
  string(67) "Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal"
  ["article_title"]=>
  string(67) "Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal"
  [2]=>
  string(150) "Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutic"
  ["short_description"]=>
  string(150) "Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutic"
  [3]=>
  string(593) "
Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutics-based immuno-oncology therapies. The deal allows Bicycle to explore its 
&#nl
The post Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(593) "
Under a strategic collaboration agreement, the companies will involve in the discovery, development and commercialisation of novel Bicycle Therapeutics-based immuno-oncology therapies. The deal allows Bicycle to explore its 
&#nl
The post Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/genentech-bicycle-therapeutics/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/genentech-bicycle-therapeutics/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:57"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7893"
  ["article_id"]=>
  string(4) "7893"
  [1]=>
  string(82) "Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC"
  ["article_title"]=>
  string(82) "Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC"
  [2]=>
  string(150) "As per the supplemental New Drug Application (sNDA), the Japanese pharma company is seeking approval of ALUNBRIG for the first-line treatment of patie"
  ["short_description"]=>
  string(150) "As per the supplemental New Drug Application (sNDA), the Japanese pharma company is seeking approval of ALUNBRIG for the first-line treatment of patie"
  [3]=>
  string(590) "
As per the supplemental New Drug Application (sNDA), the Japanese pharma company is seeking approval of ALUNBRIG for the first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK+) 
&#nl
The post Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(590) "
As per the supplemental New Drug Application (sNDA), the Japanese pharma company is seeking approval of ALUNBRIG for the first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK+) 
&#nl
The post Takeda’s ALUNBRIG gets FDA priority review for expanded indication in NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/alunbrig-fda-priority-review-nsclc/"
  ["blog_url"]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/alunbrig-fda-priority-review-nsclc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:48:57"
  ["create_at"]=>
  string(19) "2020-02-28 18:48:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "7968"
  ["article_id"]=>
  string(4) "7968"
  [1]=>
  string(102) "TrueProfile.io and RAKMHSU sign first UAE partnership to strengthen graduates’ career potential"
  ["article_title"]=>
  string(102) "TrueProfile.io and RAKMHSU sign first UAE partnership to strengthen graduates’ career potential"
  [2]=>
  string(150) "TrueProfile.io® and Ras al Khaimah Medical and Health Sciences University (RAKMHSU) have signed the first pivotal partnership in the UAE to suppo"
  ["short_description"]=>
  string(150) "TrueProfile.io® and Ras al Khaimah Medical and Health Sciences University (RAKMHSU) have signed the first pivotal partnership in the UAE to suppo"
  [3]=>
  string(528) "TrueProfile.io® and Ras al Khaimah Medical and Health Sciences University (RAKMHSU) have signed the first pivotal partnership in the UAE to support graduates in securing coveted job opportunities and pursuing higher studies overseas. TrueProfile.io, powered by the DataFlow Group, is a leader in the document verification industry. Their new partnership - the first of its kind in the UAE - provides each RAKMHSU graduate with their own verified degree certificate, a critical driver for securing...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(528) "TrueProfile.io® and Ras al Khaimah Medical and Health Sciences University (RAKMHSU) have signed the first pivotal partnership in the UAE to support graduates in securing coveted job opportunities and pursuing higher studies overseas. TrueProfile.io, powered by the DataFlow Group, is a leader in the document verification industry. Their new partnership - the first of its kind in the UAE - provides each RAKMHSU graduate with their own verified degree certificate, a critical driver for securing...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "4"
  ["category"]=>
  string(1) "4"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "65"
  ["rss_id"]=>
  string(2) "65"
  [14]=>
  string(85) "http://www.realwire.com/releases/TrueProfileio-and-RAKMHSU-sign-first-UAE-partnership"
  ["blog_url"]=>
  string(85) "http://www.realwire.com/releases/TrueProfileio-and-RAKMHSU-sign-first-UAE-partnership"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-02-28 18:49:22"
  ["create_at"]=>
  string(19) "2020-02-28 18:49:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8118"
  ["article_id"]=>
  string(4) "8118"
  [1]=>
  string(83) "Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC"
  ["article_title"]=>
  string(83) "Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC"
  [2]=>
  string(150) "The designation enables to use of JNJ-6372 to treat patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) Exon 20 insertion muta"
  ["short_description"]=>
  string(150) "The designation enables to use of JNJ-6372 to treat patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) Exon 20 insertion muta"
  [3]=>
  string(564) "
The designation enables to use of JNJ-6372 to treat patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has advanced on 
&#nl
The post Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(564) "
The designation enables to use of JNJ-6372 to treat patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has advanced on 
&#nl
The post Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/janssen-jnj-6372-nsclc/"
  ["blog_url"]=>
  string(75) "https://www.pharmaceutical-business-review.com/news/janssen-jnj-6372-nsclc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8119"
  ["article_id"]=>
  string(4) "8119"
  [1]=>
  string(81) "Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial"
  ["article_title"]=>
  string(81) "Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial"
  [2]=>
  string(150) "Planned to be branded as EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, KPI-121 showed statistically significant results for primary and"
  ["short_description"]=>
  string(150) "Planned to be branded as EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, KPI-121 showed statistically significant results for primary and"
  [3]=>
  string(589) "
Planned to be branded as EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, KPI-121 showed statistically significant results for primary and also key secondary endpoints in comparison to placebo in 
&#nl
The post Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(589) "
Planned to be branded as EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, KPI-121 showed statistically significant results for primary and also key secondary endpoints in comparison to placebo in 
&#nl
The post Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/kalas-kpi-121-stride-3-trial/"
  ["blog_url"]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/kalas-kpi-121-stride-3-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8120"
  ["article_id"]=>
  string(4) "8120"
  [1]=>
  string(149) "AbbVie receives marketing authorisation from EC to shorten MAVIRET duration for treatment-naïve genotype 3 HCV patients with compensated cirrhosis"
  ["article_title"]=>
  string(149) "AbbVie receives marketing authorisation from EC to shorten MAVIRET duration for treatment-naïve genotype 3 HCV patients with compensated cirrhosis"
  [2]=>
  string(152) "MAVIRET was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8"
  ["short_description"]=>
  string(152) "MAVIRET was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8"
  [3]=>
  string(783) "
MAVIRET was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2, 
&#nl
The post AbbVie receives marketing authorisation from EC to shorten MAVIRET duration for treatment-naïve genotype 3 HCV patients with compensated cirrhosis appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(783) "
MAVIRET was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2, 
&#nl
The post AbbVie receives marketing authorisation from EC to shorten MAVIRET duration for treatment-naïve genotype 3 HCV patients with compensated cirrhosis appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(205) "https://www.pharmaceutical-business-review.com/news/deals/abbvie-receives-marketing-authorisation-from-ec-to-shorten-maviret-duration-for-treatment-naive-genotype-3-hcv-patients-with-compensated-cirrhosis/"
  ["blog_url"]=>
  string(205) "https://www.pharmaceutical-business-review.com/news/deals/abbvie-receives-marketing-authorisation-from-ec-to-shorten-maviret-duration-for-treatment-naive-genotype-3-hcv-patients-with-compensated-cirrhosis/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8121"
  ["article_id"]=>
  string(4) "8121"
  [1]=>
  string(113) "Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19"
  ["article_title"]=>
  string(113) "Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19"
  [2]=>
  string(157) "The collaboration will also utilize the H2L2 Harbour Mice® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19"
  ["short_description"]=>
  string(157) "The collaboration will also utilize the H2L2 Harbour Mice® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19"
  [3]=>
  string(698) "
The collaboration will also utilize the H2L2 Harbour Mice® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19). These fully 
&#nl
The post Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(698) "
The collaboration will also utilize the H2L2 Harbour Mice® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19). These fully 
&#nl
The post Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(166) "https://www.pharmaceutical-business-review.com/news/mount-sinai-and-harbour-biomed-collaborate-to-advance-novel-biotherapies-to-treat-cancer-and-coronavirus-covid-19/"
  ["blog_url"]=>
  string(166) "https://www.pharmaceutical-business-review.com/news/mount-sinai-and-harbour-biomed-collaborate-to-advance-novel-biotherapies-to-treat-cancer-and-coronavirus-covid-19/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8122"
  ["article_id"]=>
  string(4) "8122"
  [1]=>
  string(68) "Novartis gets FDA nod for Isturisa to treat Cushing’s disease"
  ["article_title"]=>
  string(68) "Novartis gets FDA nod for Isturisa to treat Cushing’s disease"
  [2]=>
  string(155) "The FDA approval allows Isturisa to treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surg"
  ["short_description"]=>
  string(155) "The FDA approval allows Isturisa to treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surg"
  [3]=>
  string(562) "
The FDA approval allows Isturisa to treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still suffering from the 
&#nl
The post Novartis gets FDA nod for Isturisa to treat Cushing’s disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(562) "
The FDA approval allows Isturisa to treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still suffering from the 
&#nl
The post Novartis gets FDA nod for Isturisa to treat Cushing’s disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/novartis-isturisa-cushings-disease/"
  ["blog_url"]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/novartis-isturisa-cushings-disease/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}